Author: Anderson, Jonathon; Schauer, Jordan; Bryant, Suzanne; Graves, Cornelia R.
Title: The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report Cord-id: fxi8ss2s Document date: 2020_5_16
ID: fxi8ss2s
Snippet: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus Disease 19 (COVID-19). In this case report we summarize the use of convalescent plasma therapy and then remdesivir as a late addition in the treatment of a critically ill obstetric patient with COVID-19. The patient subsequently improved, was extubated 5 days a
Document: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus Disease 19 (COVID-19). In this case report we summarize the use of convalescent plasma therapy and then remdesivir as a late addition in the treatment of a critically ill obstetric patient with COVID-19. The patient subsequently improved, was extubated 5 days after initiation of remdesivir, was transitioned to room air 24 h later, and discharged at the completion of remdesivir therapy.
Search related documents:
Co phrase search for related documents- acute pneumonia and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- acute pneumonia and admission occur: 1
- acute pneumonia and admission ray: 1, 2
- acute pneumonia and liver enzyme: 1, 2
- acute pneumonia and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute pneumonia and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute pneumonia and lung development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute viral illness and low molecular weight heparin: 1
- additional day and admission day: 1, 2, 3, 4, 5, 6, 7
- additional day and lopinavir ritonavir: 1
- admission complete and low molecular weight heparin: 1
- admission day and liver enzyme: 1
- admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- admission day and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- liver enzyme and lopinavir ritonavir: 1, 2, 3, 4
- liver enzyme and low molecular weight heparin: 1
- lopinavir ritonavir and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- lopinavir ritonavir and low molecular weight heparin therapeutic dose: 1
- lopinavir ritonavir and lung development: 1, 2
Co phrase search for related documents, hyperlinks ordered by date